CPI Card Group Inc. (PMTS) Q2 2025 Earnings Call Transcript

CPI Card Group Inc. (PMTS) reported Q2 2025 net sales up 9% (15% excluding an accounting change) and adjusted EBITDA up 3% to $22.5 million, despite gross margin pressure from sales mix, increased tariffs, and transition costs for its new Indiana facility. The recent Arroweye acquisition was a key driver, contributing approximately $10 million in revenue and exceeding initial profitability expectations, bolstering PMTS's strategic expansion into diverse payment card markets. Consequently, the company raised its full-year net sales outlook to low double-digit to mid-teens growth, primarily due to Arroweye, while maintaining its adjusted EBITDA guidance as Arroweye's contribution offsets higher tariff impacts and an unfavorable sales mix. PMTS noted it has ample chip inventory and is assessing potential impacts from recently proposed semiconductor chip tariffs, which are not yet factored into its current outlook.

Analysis

CPI Card Group (PMTS) delivered a strategically positive second quarter, with reported net sales increasing 9% to $129.8 million, or a more indicative 15% when excluding a one-time, non-cash accounting change. The core narrative is the successful integration of the Arroweye acquisition, which contributed nearly $10 million in revenue in less than two months, exceeding both sales and profitability expectations. This acquisition is critical to the company's strategy, diversifying its revenue into new segments like fintech and healthcare payment cards with minimal customer overlap. Organic growth remains robust, with the Secure Card business growing over 15% in the first half and the Card@Once SaaS solution expanding over 20%. However, this strong top-line performance was offset by significant gross margin compression, which declined to 30.9% from 35.7% a year prior. This pressure stems from a sales mix shift towards larger, lower-margin issuers, an increased full-year tariff forecast of approximately $5 million, and roughly $3 million in duplicate operating costs from the transition to a new Indiana facility. Consequently, while the full-year sales outlook was raised to low double-digit to mid-teens growth, the adjusted EBITDA guidance was maintained at mid- to high single-digit growth, indicating that near-term cost headwinds are absorbing the benefits from the accretive acquisition. A significant emerging risk is the newly proposed tariff on semiconductor chips, which is not yet reflected in guidance but is somewhat mitigated by the company's ample chip inventory.

Key Decisions for Investors

• Focus on the successful integration of the Arroweye acquisition, which is outperforming expectations and serves as the primary driver for the upgraded full-year revenue guidance.
• Monitor gross margin trends closely, as the path to improved profitability hinges on the company's ability to offset the $5 million tariff impact and realize efficiencies from its new Indiana facility in 2026.
• Treat the newly proposed semiconductor chip tariff as a material, unquantified risk; while the company's large inventory provides a near-term shield, its long-term implementation could significantly alter the industry's cost dynamics.
• Evaluate the company's growth-versus-profitability profile, as the maintained EBITDA guidance suggests near-term headwinds are fully offsetting the financial benefits of strong revenue growth and the accretive acquisition.